New York Stock Exchange (NYSE) · Financial Services
Federated Hermes, Inc. Class B FHI
MonitorScore band: 60–70
The thesis, in one sentence
An asset manager with most of its assets in money-market funds and owner earnings that equal reported profit, but with no margin of safety: the two anchors that assume no growth both sit below the price.
Written for this site in plain English, without figures. The arithmetic is in the full report.
The thesis is from the deep report of 2026-08-25; the verdict badge reflects the latest scoring of 2026-09-06.
Key risks
- Voluntary fee waivers return if short-term rates are cut toward zero
- The franchise does not grow organically; asset growth is market appreciation
- Buybacks, not organic growth, have driven the compounding
What would change the verdict
- Revenue falls as fee waivers return for two consecutive quarters
- Operating margin compresses back to the level of two years ago
- Days sales outstanding rise for two consecutive quarters
- Buybacks stop or shares are issued for an acquisition
Read it yourself
Step five of the method is the reader's: open the latest annual or quarterly report and read it before acting on anything here. A score is a summary, and a summary is not understanding.
Next report expected 2026-10-29. The deep report was written against the filings available on 2026-08-25; anything published since is not in it.
Price, one year
DCF valuation range
range of the DCF modelsbase casetoday's price
Valuation range, shape only. Figures in the full version.
Monte Carlo outcome shape
scenarios below today's pricescenarios above today's pricetoday's price
Distribution of simulated outcomes around today's price. Bar heights only; the scale and the percentiles are in the full version.
Chapter one: Executive summary (1 page: thesis, estimated value, verdict)
Deep-value: FHI — Federated Hermes, Inc. (Class B, NYSE)
Analysis date: 2026-08-25 · Reference price: USD … (close 2026-08-24) · Shares outstanding: 74.909 mil. (2026-06-30) · Market cap: USD 4.85 bn · Reporting currency: USD (identical to the price currency — no conversion needed)
Primary sources: 10-K FY2025 (filed 2026-02-27), 10-K FY2024/FY2023/FY2022/FY2021, 10-Q Q1 2026 (2026-05-01), 10-Q Q2 2026 (2026-07-31), 10-Q Q1–Q3 2025, DEF 14C from 2026-03-17, Q2 2026 earnings call transcript (2026-07-31), data pack data-pack-FHI-20260824.md, simulation mc-FHI-20260825.json.
Executive summary (1 page: thesis, estimated value, verdict)
The thesis in three sentences. Federated Hermes is an asset manager founded in 1955, fully controlled by the Donahue family through 9,000 Class A shares held in a voting trust, which manages USD 911.6 bn (2026-06-30) of which USD 676.9 bn — 74% — are money market funds. The business has the economics of a liquidity tax: near-zero fixed capital (capex USD 2.8 mil. in 2025 versus depreciation of 22.3 mil.), 2,091 employees managing USD 432 mil. of assets per head, ROE of 35%, and net profit that practically equals free cash flow to the shareholder. The price, however, no longer reflects even half the pessimism it embedded two years ago: the stock rose from USD 33.86 (2023-12-31) to …, i.e. … in 32 months, while EPS grew from 3.40 to 5.38 (…) — the rest is multiple re-rating.
The flow choice (detailed in the valuation chapter). FHI's reported CFO is systematically distorted by the Consolidated Investment Companies: the net securities purchases made by these funds appear as an operating outflow (USD 146.1 mil. in 2025, 94.4 mil. ttm), even though the money is mostly third parties' and comes in through financing (minority contributions of 163.9 mil. in 2025). Whoever takes "CFO − capex" at face value gets USD 294.6 mil. for 2025 and wrongly concludes that the 403.3 mil. profit is low-quality. After stripping out the consolidated-fund transactions, subtracting minority interests, and treating stock compensation as a real cost (not added back), FCFE 2025 = USD 403.1 mil., i.e. 99.95% of the 403.3 mil. attributable net profit. Over the trailing 12 months (through 2026-06-30), FCFE = USD 435.2 mil., a 9.0% yield at the current price. The normalized base used in the DCF: USD 410 mil.
Estimated value. Five triangulated models produce a brutally wide range, and the width is the main message:
| # | Model | Value/share | MOS vs … |
|---|---|---|---|
| 1 | Bear DCF FCFE (OE 330, g1 0%, r 10.5%, gt 1.5%) | 44.81 | … |
| 2 | Base DCF FCFE (OE 410, g1 4%, r 9.5%, gt 2%) | 81.05 | … |
| 3 | Bull DCF FCFE (OE 460, g1 6.5%, r 9%, gt 2.5%) | 117.74 | … |
| 4 | Greenwald EPV (410/0.095, no growth) | 57.62 | … |
| 5 | 5-year historical multiples (11.5× on normalized EPS 5.10) | 58.65 | … |
Monte Carlo (20,000 scenarios, same central assumptions as model 2): median intrinsic value …, median MOS …, probability of undervaluation …, but a P5–P95 range from … to ….
Verdict: WATCH, don't buy at …. The business deserves to be owned; today's price offers no margin of safety. The three anchors that don't depend on a ten-year growth forecast — EPV (…), historical multiples (…), and analyst consensus (average target USD 61.14, "hold," 7 analysts) — all say the same thing: the stock is fairly valued to slightly expensive. The only model that gives serious upside is the DCF, and it has … of its value in the terminal term and assumes 4% annual growth for ten years at a company whose money-market share has been flat for the last 7.5 years (gained share in 14 quarters, lost it in 14) and whose long-term assets had net outflows in both prior years. Accumulation threshold: below USD 55, where EPV turns positive and the zero-rate scenario stops being a permanent capital loss. Position size, if taken: small — the 143-percentage-point P5–P95 range doesn't support a high-conviction position.
Figures were removed from this excerpt. The full report opens free for five tickers a week — see what's open now.
Full report contents
- Executive summary (1 page: thesis, estimated value, verdict)
- 🔒 The business and its moat (how it makes money, competitive advantage, durability) (Available in the full report)
- 🔒 Management and capital allocation (track record, buybacks/dividends/acquisitions, skin in the game) (Available in the full report)
- 🔒 What changed in the last 4 quarters (line-by-line balance sheet from the data pack, margins, cash conversion — explain EVERY large swing) (Available in the full report)
- 🔒 Balance sheet analysis — Quality of Earnings (Thornton O'Glove method) (Available in the full report)
- 🔒 CEO profile — Outsider traits (William Thorndike method) (Available in the full report)
- 🔒 Accounting red flags (accruals, dilution, one-offs, accounting policy changes) (Available in the full report)
- 🔒 Triangulated valuation (conservative DCF with explicit assumptions + earnings power value + 5-year historical multiples + Monte Carlo from step 5; a range, not a point) (Available in the full report)
- 🔒 Pre-mortem (why the thesis could be wrong — 3 concrete scenarios) (Available in the full report)
- 🔒 Verdict compared with the tracker's GBL score (convergence/divergence and why) (Available in the full report)
Evaluation history
| Date | Verdict |
|---|---|
| 2026-08-23 | Interesting |
| 2026-08-25 | Monitor |
| 2026-09-06 | Monitor |
Want the rest of this report?
Subscribe to get one full deep report a week by email, the day before it opens on the site.